Rituxan Launch For Arthritis, Tysabri Return Expected In Mid-’06, Biogen Says

Biogen Idec could launch Rituxan (rituximab) for rheumatoid arthritis and relaunch Tysabri (natalizumab) for multiple sclerosis by mid-2006, CFO Peter Kellogg said during an Oct. 26 earnings call